Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial-Reference-Cited by-同舟云学术

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

Published:2012-01 Issue:1 Volume:13 Page:89-99
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Lehtinen Matti,Paavonen Jorma,Wheeler Cosette M,Jaisamrarn Unnop,Garland Suzanne M,Castellsagué Xavier,Skinner S Rachel,Apter Dan,Naud Paulo,Salmerón Jorge,Chow Song-Nan,Kitchener Henry,Teixeira Júlio C,Hedrick James,Limson Genara,Szarewski Anne,Romanowski Barbara,Aoki Fred Y,Schwarz Tino F,Poppe Willy A J,De Carvalho Newton S,Germar Maria Julieta V,Peters Klaus,Mindel Adrian,De Sutter Philippe,Bosch F Xavier,David Marie-Pierre,Descamps Dominique,Struyf Frank,Dubin Gary

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. A controlled trial of a human papillomavirus type 16 vaccine;Koutsky;N Engl J Med,2002

2. The beginning of the end for cervical cancer?;Crum;N Engl J Med,2002

3. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial;Paavonen;Lancet,2007

4. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women;Paavonen;Lancet,2009

5. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years;Lancet,2009

Cited by 556 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced technologies towards improved HPV diagnostics;Journal of Medical Virology;2024-01-31

2. The quality of life of frequently vs. infrequently screened HPV vaccinated women;Quality of Life Research;2024-01-18

3. Risk of progression of cervical intraepithelial neoplasia grade 2 in human papillomavirus–vaccinated and unvaccinated women: a population-based cohort study;American Journal of Obstetrics and Gynecology;2023-12

4. Prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Chinese girls and women aged 9 to 45 years, 2018–2020;Human Vaccines & Immunotherapeutics;2023-12

5. Comparative efficacy of human papillomavirus vaccines: systematic review and network meta-analysis;Expert Review of Vaccines;2023-11-27